CDTX - NASDAQ
Cidara Therapeutics, Inc.
$221.38
+0.0000%Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
At a Glance
Live SnapshotCidara Therapeutics, Inc. Management Team
Mr. Jim Beitel M.B.A.
Chief Business Officer
Mr. Frank L. Karbe M.B.A.
Chief Financial Officer
Dr. Nicole Davarpanah J.D., M.D.
Chief Medical Officer
Mr. Shane M. Ward J.D.
Chief Operating Officer & Corporate Secretary
Compensation
$620,940
Dr. Leslie Tari Ph.D.
Chief Scientific Officer
Compensation
$688,050
Dr. Kevin M. Forrest Ph.D.
Founder & Chief Strategy Officer
Compensation
$333,313
Dr. Jeffrey L. Stein Ph.D.
President, Chief Executive Officer & Executive Director
Compensation
$1,098,550
Dr. Preetam Shah M.B.A., Ph.D.
Principal Accounting Officer
Compensation
$577,850
Ms. Corrina Pavetto
Senior Vice President of Clinical Development
Ms. Allison Lewis CCP, SPHR
Senior Vice President of People & Culture
Cidara Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $100.00M and sold $2.22M worth of CDTX shares, resulting in $97.78M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
10.0K
2.19M
-2.2M
-$2.19M
6-9 Months
0
0.00
474
29.80K
-30K
-$30K
9-12 Months
2.3M
100.00M
0
0.00
+100.0M
+$100.00M
Top Buyers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$100.00M
Top Sellers
Ward Shane
Officer: Coo & Clo
$2.19M
Davarpanah Nicole Negar
Officer: Chief Medical Officer
$30K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $97.78M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.
SEC Filings
CDTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 18, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 03, 2024 | July 18, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | March 04, 2024 | April 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 22, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | November 10, 2022 | December 15, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 22, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 23, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | April 29, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 26, 2019 | June 17, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 27, 2018 | April 27, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.